Halozyme Therapeutics (HALO) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed Vaxcyte (PCVX) over the past year, gaining 67.8% versus a gain of 59.9%. Over five years, HALO leads with a +193.4% price change compared with +174.3% for PCVX. Halozyme Therapeutics is the larger company by market cap ($12.57 billion vs $9.96 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HALO | PCVX |
|---|---|---|
| Share price | $110.79 | $66.96 |
| Market cap | $12.57B | $9.96B |
| 1-day change | +0.98% | +0.39% |
| YTD return | +64.62% | +45.12% |
| 1-year return | +67.81% | +59.92% |
| 5-year return | +193.41% | +174.31% |
| P/E ratio (TTM) | 32.39 | — |
| Forward P/E | 10.29 | — |
| EPS (TTM) | $3.42 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.40B | — |
| Revenue growth (YoY) | +37.55% | — |
| Net income (latest FY) | $316.89M | $-766.63M |
| Gross margin | 83.62% | — |
| Operating margin | 33.58% | — |
| Net margin | 22.69% | — |
| 52-week high | $116.85 | $90.75 |
| 52-week low | $61.23 | $39.87 |
| Distance from 52-week high | -5.19% | -26.21% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -10.14% | +65.59% |
| Average volume | 2.17M | 1.50M |
| Shares outstanding | 113.50M | 148.81M |
| Employees | 423 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
HALO vs PCVX FAQ
Which is bigger, Halozyme Therapeutics or Vaxcyte?
Halozyme Therapeutics (HALO) is larger, with a market capitalization of $12.57B compared with $9.96B for Vaxcyte (PCVX).
Which stock has performed better over the past year, HALO or PCVX?
HALO returned +67.81% over the past 12 months, compared with +59.92% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are Halozyme Therapeutics and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.